abacavir/lamivudine teva 600 mg / 300 mg tabletti, kalvopäällysteinen
teva b.v. - lamivudine, abacavir - tabletti, kalvopäällysteinen - 600 mg / 300 mg - lamivudiini ja abakaviiri
duloxetine sandoz 30 mg enterokapseli, kova
sandoz a/s sandoz a/s - duloxetini hydrochloridum - enterokapseli, kova - 30 mg - duloksetiini
duloxetine sandoz 60 mg enterokapseli, kova
sandoz a/s sandoz a/s - duloxetini hydrochloridum - enterokapseli, kova - 60 mg - duloksetiini
betahistine abbott 24 mg tabletti, suussa hajoava
abbott healthcare products b.v - betahistini dihydrochloridum - tabletti, suussa hajoava - 24 mg - betahistiini
methylphenidate stada 20 mg säädellysti vapauttava kapseli, kova
stada arzneimittel ag - methylphenidate hydrochloride - säädellysti vapauttava kapseli, kova - 20 mg - metyylifenidaatti
methylphenidate stada 30 mg säädellysti vapauttava kapseli, kova
stada arzneimittel ag - methylphenidate hydrochloride - säädellysti vapauttava kapseli, kova - 30 mg - metyylifenidaatti
methylphenidate stada 40 mg säädellysti vapauttava kapseli, kova
stada arzneimittel ag - methylphenidate hydrochloride - säädellysti vapauttava kapseli, kova - 40 mg - metyylifenidaatti
methylphenidate stada 60 mg säädellysti vapauttava kapseli, kova
stada arzneimittel ag - methylphenidate hydrochloride - säädellysti vapauttava kapseli, kova - 60 mg - metyylifenidaatti
betahistin abbott 16 mg tabletti
abbott healthcare products b.v - betahistini dihydrochloridum - tabletti - 16 mg - betahistiini
dasatinib accordpharma
accord healthcare s.l.u. - dasatinibin - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiset aineet - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.